These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37577753)

  • 1. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial.
    Mendell JR; Sahenk Z; Lehman KJ; Lowes LP; Reash NF; Iammarino MA; Alfano LN; Lewis S; Church K; Shell R; Potter RA; Griffin DA; Hogan M; Wang S; Mason S; Darton E; Rodino-Klapac LR
    Muscle Nerve; 2024 Jan; 69(1):93-98. PubMed ID: 37577753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR).
    Zaidman CM; Proud CM; McDonald CM; Lehman KJ; Goedeker NL; Mason S; Murphy AP; Guridi M; Wang S; Reid C; Darton E; Wandel C; Lewis S; Malhotra J; Griffin DA; Potter RA; Rodino-Klapac LR; Mendell JR
    Ann Neurol; 2023 Nov; 94(5):955-968. PubMed ID: 37539981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy.
    Mendell JR; Shieh PB; McDonald CM; Sahenk Z; Lehman KJ; Lowes LP; Reash NF; Iammarino MA; Alfano LN; Sabo B; Woods JD; Skura CL; Mao HC; Staudt LA; Griffin DA; Lewis S; Wang S; Potter RA; Singh T; Rodino-Klapac LR
    Front Cell Dev Biol; 2023; 11():1167762. PubMed ID: 37497476
    [No Abstract]   [Full Text] [Related]  

  • 4. Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy.
    Mendell JR; Proud C; Zaidman CM; Mason S; Darton E; Wang S; Wandel C; Murphy AP; Mercuri E; Muntoni F; McDonald CM
    Pediatr Neurol; 2024 Apr; 153():11-18. PubMed ID: 38306745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delandistrogene Moxeparvovec: First Approval.
    Hoy SM
    Drugs; 2023 Sep; 83(14):1323-1329. PubMed ID: 37566211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy.
    Zaidman CM; Goedeker NL; Aqul AA; Butterfield RJ; Connolly AM; Crystal RG; Godwin KE; Hor KN; Mathews KD; Proud CM; Kula Smyth E; Veerapandiyan A; Watkins PB; Mendell JR
    J Neuromuscul Dis; 2024; 11(3):687-699. PubMed ID: 38607761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.
    Mendell JR; Sahenk Z; Lehman K; Nease C; Lowes LP; Miller NF; Iammarino MA; Alfano LN; Nicholl A; Al-Zaidy S; Lewis S; Church K; Shell R; Cripe LH; Potter RA; Griffin DA; Pozsgai E; Dugar A; Hogan M; Rodino-Klapac LR
    JAMA Neurol; 2020 Sep; 77(9):1122-1131. PubMed ID: 32539076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States.
    Klimchak AC; Sedita LE; Rodino-Klapac LR; Mendell JR; McDonald CM; Gooch KL; Malone DC
    J Mark Access Health Policy; 2023; 11(1):2216518. PubMed ID: 37261034
    [No Abstract]   [Full Text] [Related]  

  • 9. Delandistrogene moxeparvovec (Elevidys) for Duchenne muscular dystrophy.
    Med Lett Drugs Ther; 2023 Oct; 65(1686):159-160. PubMed ID: 37755693
    [No Abstract]   [Full Text] [Related]  

  • 10. [How safe is gene therapy? : Second death after Duchenne therapy].
    Horn S; Fehse B
    Inn Med (Heidelb); 2024 Jun; 65(6):617-623. PubMed ID: 38748280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec.
    Asher D; Dai D; Klimchak AC; Sedita LE; Gooch KL; Rodino-Klapac L
    Mol Ther Methods Clin Dev; 2023 Sep; 30():474-483. PubMed ID: 37674905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity of remote live stream video evaluation of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.
    P Lowes L; Alfano LN; Iammarino MA; Reash NF; Giblin K; Hu L; Yu L; Wang S; Salazar R; Mendell JR
    PLoS One; 2024; 19(5):e0300700. PubMed ID: 38753764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.
    Muntoni F; Domingos J; Manzur AY; Mayhew A; Guglieri M; ; Sajeev G; Signorovitch J; Ward SJ
    PLoS One; 2019; 14(9):e0221097. PubMed ID: 31479456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the
    Potter RA; Griffin DA; Heller KN; Peterson EL; Clark EK; Mendell JR; Rodino-Klapac LR
    Hum Gene Ther; 2021 Apr; 32(7-8):375-389. PubMed ID: 33397205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of disease progression and genetic correlation in ambulatory Iranian boys with Duchenne muscular dystrophy.
    Zamani G; Hosseinpour S; Ashrafi MR; Mohammadi M; Badv RS; Tavasoli AR; Akbari MG; Bereshneh AH; Malamiri RA; Heidari M
    BMC Neurol; 2022 May; 22(1):162. PubMed ID: 35501714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls.
    Mendell JR; Khan N; Sha N; Eliopoulos H; McDonald CM; Goemans N; Mercuri E; Lowes LP; Alfano LN;
    J Neuromuscul Dis; 2021; 8(4):469-479. PubMed ID: 33523015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.
    Kinali M; Arechavala-Gomeza V; Feng L; Cirak S; Hunt D; Adkin C; Guglieri M; Ashton E; Abbs S; Nihoyannopoulos P; Garralda ME; Rutherford M; McCulley C; Popplewell L; Graham IR; Dickson G; Wood MJ; Wells DJ; Wilton SD; Kole R; Straub V; Bushby K; Sewry C; Morgan JE; Muntoni F
    Lancet Neurol; 2009 Oct; 8(10):918-28. PubMed ID: 19713152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial.
    Finkel RS; McDonald CM; Lee Sweeney H; Finanger E; Neil Knierbein E; Wagner KR; Mathews KD; Marks W; Statland J; Nance J; McMillan HJ; McCullagh G; Tian C; Ryan MM; O'Rourke D; Müller-Felber W; Tulinius M; Burnette WB; Nguyen CT; Vijayakumar K; Johannsen J; Phan HC; Eagle M; MacDougall J; Mancini M; Donovan JM;
    J Neuromuscul Dis; 2021; 8(5):769-784. PubMed ID: 34120912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.